louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05826405: Efficacy and Safety of Oral Cashew Nut Immunotherapy in Children (CAJESITO)
Official title: Efficacy and Safety of Oral Cashew Nut Immunotherapy in Children (CAJESITO)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Allergy;Food
Allergy, Nut
Keywords: allergy
food allergy
cashew nut allergy
oral immunotherapy
pistachio allergy
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2023-04-24
Enrollment: 40
Sex: ALL
Minimum age (years): 0
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients from 0 to 18 years old followed in allergology at the University Hospital of Nancy benefiting from oral immunotherapy with cashew nuts for at least 18 months as of 02/28/2023

Brief summary: The objectives of the CAJESITO study are (i) to assess the tolerance of oral cashew nut immunotherapy, by describing the frequency and severity of allergic reactions during oral cashew nut immunotherapy and (ii )to assess the risk factors for severe allergic reactions during oral cashew nut immunotherapy (predictive factors, associated factors.


Eligibility criteria: Inclusion Criteria:

* Patients under the age of 18 with a proven allergy to cashew nuts and followed in the pediatric allergology unit of the University Hospital of Nancy.
* Patients who have received oral cashew nut immunotherapy for at least 18 months as of 02/28/2023

Exclusion Criteria:

* Patients who have received oral cashew nut immunotherapy for less than 18 months.
* Patients lost to follow-up for more than 3 years, i.e. last consultation dating from 2020 or earlier

Primary outcomes:
measure: Number of allergic reaction
timeFrame: during 6 months
Secondary outcomes:
measure: Predictive factor of good tolerance
timeFrame: during 6 months
measure: antibody variation
timeFrame: during 6 months
measure: sustained unresponsiveness
timeFrame: 9 months
measure: oral tolerance of pistachio
timeFrame: 6 months
measure: Predictive factor of good tolerance
timeFrame: 6 months
measure: Predictive factor of good tolerance
timeFrame: 6 months
measure: Predictive factor of good tolerance
timeFrame: 6 months
measure: Predictive factor of good tolerance
timeFrame: 6 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03622398: Highly Cross-linked Polyethylene in Total Knee Arthroplasty
Official title: Highly Cross-linked Polyethylene Versus Compression Mold Conventional Polyethylene in Cruciate-substituting Total Knee Arthroplasty in Young Patients, a Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Knee Arthroplasty, Total
Keywords: total knee arthroplasty
highly cross-linked polyethylene
Lead sponsor: Ewha Womans University
Sponsor class: OTHER
First posted: 2018-08-09
Enrollment: 125
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Total knee arthroplasty is performed on patients with knee osteoarthritis. One group will receive a highly cross-linked polyethylene liner and one group will receive a conventional polyethylene liner. Other parts of procedures will be the same.
Primary purpose: TREATMENT

Brief summary: The aim of this study was to determine clinical and radiographic results after posterior cruciate-substituting total knee arthroplasties with highly cross-linked polyethylene in one knee and compression mold conventional polyethylene in the contralateral knee in the same patients.


Eligibility criteria: Inclusion Criteria:

* Younger than 65 years old
* with end stage knee arthritis bad enough for knee replacement

Exclusion Criteria:

* inflammatory arthritis
* combined foot and ankle disorders.
* dementia
* patient older than 65 years old.

Primary outcomes:
measure: Knee society knee score
timeFrame: minimum 10 year follow up after the index surgery
Secondary outcomes:
measure: WOMAC(Western Ontario and McMaster Universities) Scores
timeFrame: minimum 10 year follow up after the index surgery
measure: Range of motion
timeFrame: minimum 10 year follow up after the index surgery
Other outcomes:
Locations:
Study officials:
References:
citation: Kim YH, Oh JH, Oh SH. Osteolysis around cementless porous-coated anatomic knee prostheses. J Bone Joint Surg Br. 1995 Mar;77(2):236-41.
citation: Mikulak SA, Mahoney OM, dela Rosa MA, Schmalzried TP. Loosening and osteolysis with the press-fit condylar posterior-cruciate-substituting total knee replacement. J Bone Joint Surg Am. 2001 Mar;83(3):398-403. doi: 10.2106/00004623-200103000-00012.
citation: Rodriguez JA, Bhende H, Ranawat CS. Total condylar knee replacement: a 20-year followup study. Clin Orthop Relat Res. 2001 Jul;(388):10-7.
citation: Hodrick JT, Severson EP, McAlister DS, Dahl B, Hofmann AA. Highly crosslinked polyethylene is safe for use in total knee arthroplasty. Clin Orthop Relat Res. 2008 Nov;466(11):2806-12. doi: 10.1007/s11999-008-0472-4. Epub 2008 Sep 10.
citation: Long WJ, Levi GS, Scuderi GR. Highly cross-linked polyethylene in posterior stabilized total knee arthroplasty: early results. Orthop Clin North Am. 2012 Nov;43(5):e35-8. doi: 10.1016/j.ocl.2012.07.005. Epub 2012 Sep 27.
Clinical trial NCT01028898: Abnormal Expression Proteins, Mitochondrial DNA and miRNA of Irritable Bowel Syndrome
Official title: Screening and Identification of Abnormal Expression Proteins and miRNA From Colonic Mucosa of Patients With Irritable Bowel Syndrome.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Irritable Bowel Syndrome
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Colonic Diseases
Colonic Diseases, Functional
Keywords: IBS
proteomics
fluorescent quantitation polymerase chain reaction
Western blot
immunohistochemistry staining (IHC)
ATP content
micRNA
Lead sponsor: Chinese PLA General Hospital
Sponsor class: OTHER
First posted: 2009-12-09
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: IBS patients (IBS-D and IBS-C)and healthy control

Brief summary: In the investigators study, the investigators will focus on the screening of the related proteins and miRNA to IBS in order to reveal the possible clues or molecular mechanism for this disorder.

Detailed description: For the proteomic procedures, Our study groups extracted proteins from the cecum and sigmoid colon samples and ran on the two-dimensional gel electrophoresis (2-DE). The proteins on 2-DE were visualized by the silver stain, and then gel maps were scanned and analyzed with the Image Master 2D Elite. The obvious abnormal protein spots were identified by the mass spectrometry. Western blot 、 immunohistochemistry 、 mRNA and miRNA were also performed for further verification of the proteins.

Eligibility criteria: Inclusion Criteria:

* Patients with symptoms meeting Rome III criteria for diagnosis of IBS-C and IBS-D

Exclusion Criteria:

* Patients with organic illnesses or a history of major abdominal surgery
* Major psychotic episode, mental retardation or dementia
* Pregnant women and lactational women
* Postinfectious IBS, PI-IBS

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Chinese PLA General Hospital
name: YANG Yun-sheng, MD
role: STUDY_CHAIR
affiliation: Chinese PLA General Hospital
name: ZHANG Chun-yan, doctor
role: PRINCIPAL_INVESTIGATOR
affiliation: Chinese PLA General Hospital
name: WANG Weifeng, doctor
role: PRINCIPAL_INVESTIGATOR
affiliation: Chinese PLA General Hospital
name: YAO XIN, DOCTOR
role: PRINCIPAL_INVESTIGATOR
affiliation: Chinese PLA General Hospital
name: PENG LIHUA, DOCTOR
role: PRINCIPAL_INVESTIGATOR
affiliation: Chinese PLA General Hospital
name: YU YUANZI, DOCTOR
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wang WF, Li X, Guo MZ, Chen JD, Yang YS, Peng LH, Wang YH, Zhang CY, Li HH. Mitochondrial ATP 6 and 8 polymorphisms in irritable bowel syndrome with diarrhea. World J Gastroenterol. 2013 Jun 28;19(24):3847-53. doi: 10.3748/wjg.v19.i24.3847.
Clinical trial NCT01849198: Accelerometry at the Neck: Comparison With m. Adductor Pollicis Stimulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Feasibility of Measurement of a Neuromuscular Block at the m. Trapezius
Keywords: accelerometry
neuromuscular block
m. trapezius
Lead sponsor: Kreiskrankenhaus Dormagen
Sponsor class: OTHER
First posted: 2013-05-08
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: Accelerometric Assessment of neuromuscular block during anaesthesia is routinely performed at the M. adductor pollicis. However, many operations require positioning of the patients with arms attached to the body. In these situations, the anaesthesiologist has no access to the m.adductor pollicis.

In this study, a new position of accelerometry at the neck is evaluated: Stimulation of the n. accessorius with accelerometry of the m. trapezius.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing general anaesthesia with endotracheal intubation
* weight 50-90 kg

Exclusion Criteria:

* Pregnancy
* allergy to one of the drugs used
* risk of pulmonary aspiration
* expected difficulties with endotracheal intubation
* intake of drugs known to influence neuromuscular block
* infection (CRP \> 0,5 mg/dl, leukocyte count \> 12000/µl)

Primary outcomes:
measure: Recovery to a train of four ratio of 0.9
timeFrame: 60 minutes
Secondary outcomes:
measure: onset of neuromuscular block
timeFrame: 10 min
Other outcomes:
Locations:
city: Dormagen
country: Germany
facility: KKH Dormagen
Study officials:
References:
citation: Soltesz S, Stark C, Noe KG, Anapolski M, Mencke T. Comparison of the trapezius and the adductor pollicis muscle as predictor of good intubating conditions: a randomized controlled trial. BMC Anesthesiol. 2017 Aug 17;17(1):106. doi: 10.1186/s12871-017-0401-8.
citation: Soltesz S, Stark C, Noe KG, Anapolski M, Mencke T. Monitoring recovery from rocuronium-induced neuromuscular block using acceleromyography at the trapezius versus the adductor pollicis muscle: an observational trial. Can J Anaesth. 2016 Jun;63(6):709-17. doi: 10.1007/s12630-016-0609-y. Epub 2016 Feb 10.
Clinical trial NCT06144398: Single Use Flexible Bronchoscopes in Interventional Pulmonary Procedures
Official title: Single Use Versus Standard Flexible Bronchoscopes in Interventional Pulmonary Procedures: an Open Label Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atelectasis
Hemoptysis
Stridor
Keywords: Bronchoscopy
Single Use Flexible Bronchoscope
Interventional Pulmonology
Lead sponsor: Clinical Hospital Centre Zagreb
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Single Use Flexible bronchoscopes have gained popularity in recent years and are becoming technologically more advanced. They are widely accepted and used in everyday practice for simple procedures. The aim of this study is to evaluate single use flexible bronchoscopes in more advanced settings, such as interventional pulmonary procedures.


Eligibility criteria: Inclusion Criteria:

* All patients requiring an interventional pulmonary procedure during the study period
* Signed informed consent

Exclusion Criteria:

* Any patient with a contraindication for rigid and/or flexible bronchoscopy
* Coagulopathy (PV INR \> 1.3)
* Thrombocytopenia (\<50x10\*9 or anemia (Hgb \<80 g/L)
* DOAC, LMWH or antiplatelet drug therapy
* Thrombophilia, history of pulmonary embolism or deep vein thrombosis
* Contraindication for endobronchial application of adrenaline
* Uncontrolled coronary artery disease, cerebrovascular disease or arrhythmia
* Uncontrolled pulmonary hypertension
* Cardiovascular decompensation
* Severe hypoxia (PaO2 \<60mmHg, SaO2 \<90% with an FiO2 \>=60%)
* Cervical spine instability

Primary outcomes:
measure: Overall performance
timeFrame: through study completion, an average of 12 months
Secondary outcomes:
measure: Functionality, handle and interface
timeFrame: through study completion, an average of 12 months
measure: Suction
timeFrame: through study completion, an average of 12 months
measure: Image quality
timeFrame: through study completion, an average of 12 months
measure: Bleeding control
timeFrame: through study completion, an average of 12 months
measure: Compatibility
timeFrame: through study completion, an average of 12 months
Other outcomes:
Locations:
city: Zagreb
country: Croatia
facility: University Hospital Centre Zagreb
Study officials:
References:
Clinical trial NCT00757198: Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.
Official title: Requirement of Analgesics After Two Remifentanil Dosing Regimen in Cardiac Surgery.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Pain
Keywords: pain, postoperative, opioid, PCA, cardiac surgery
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
First posted: 2008-09-23
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Prospective double blind study comparing two remifentanil dosing protocols (0.1 and 0.3 mcg/kg/min) during cardiac surgery. Main outcome measures are postoperative opioid requirements (PCA oxycodone) and postoperative pain (VAS, verbal rating scale).


Eligibility criteria: Inclusion Criteria:

* Coronary artery bypass grafting patients

Exclusion Criteria:

* Psychiatric disorders, sleep apnea, cardiac insufficiency

Primary outcomes:
measure: Postoperative opioid (oxycodone) consumption
timeFrame: Postoperatively 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Kuopio
country: Finland
facility: Kuopio University hospital
Study officials:
affiliation: Department of Anesthesiology and Intensive Care, Kuopio University hospital, Kuopio, Finland
name: Pasi Lahtinen, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04571398: A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy
Official title: A Study of ApricityRx™ Digital Therapeutic for Management of Immune-Related Adverse Events in Patients on Immuno-Oncology Therapy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cancer
Keywords: cancer
immunotherapy
checkpoint inhibitors
immune-related adverse events
Lead sponsor: Apricity Health, Inc
Sponsor class: INDUSTRY
First posted: 2020-10-01
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subject with a confirmed cancer diagnosis and prescribed checkpoint inhibitor therapy.

Brief summary: Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.


Eligibility criteria: Inclusion Criteria:

* Confirmed cancer diagnosis
* Prescribed treatment with immune-checkpoint inhibitor
* Age ≥ 18 years
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Uncomfortable with or unwilling to use digital or mobile technology
* Lack of a smart phone with compatible operating systems: iOS version 10 and above, or Android 6.0 Marshmallow
* Presence of any medical, psychological or social condition that, in the opinion of the investigator, would preclude participation in this study.

Primary outcomes:
measure: Evaluate digital therapeutic mobile app to capture and transmit to care team patient-generated health data and access education content on IO and irAEs
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Columbia University Irving Medical Center
state: New York
Study officials:
affiliation: Columbia University
name: Brian Henick, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03886298: Radiofrequency Splanchnic Denervation Versus Retrocrural Neurolytic Celiac Block for Pancreatic Cancer Pain
Official title: For Patients With Pancreatic Cancer Pain, Does Radiofrequency Splanchnic Denervation Isprovide a Similar Analgesia as Neurolytic Celiac Block
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Chronic Pain
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-03-22
Enrollment: 60
Sex: ALL
Minimum age (years): 16
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators will evaluate the analgesic efficacy of radiofrequency splanchnic nerve denervation versus neurolytic retrocrural celiac denervation for patients with abdominal pain due to cancer pancreas


Eligibility criteria: Inclusion Criteria:

* patients with abdominal pain due to cancer pancreas

Exclusion Criteria:

* coagulopathy
* infection at site of the procedure

Primary outcomes:
measure: the percentage of patients that gain more than 50% reduction of their pain on VAS pain score
timeFrame: 6 months postoperatively
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Diab
state: Assuit
Study officials:
References:
Clinical trial NCT05422898: Discussing COVID-19 Vaccines in Private Facebook Groups
Official title: Empathic Engagement With the COVID-19 Vaccine Hesitant in Private Facebook Groups
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Keywords: vaccine hesitancy
social media
health behavior
Lead sponsor: George Washington University
Sponsor class: OTHER
First posted: 2022-06-21
Enrollment: 508
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: As the COVID-19 pandemic persists, a sizable proportion of the U.S. population remains unvaccinated and at high risk of death and serious illness from COVID-19. Vaccine hesitancy, fueled by the proliferation of vaccine misinformation on social media, is one factor contributing to lack of vaccination. Current attempts to overcome vaccine misinformation focus on correcting or debunking falsehoods. Although debunking strategies are important components to any public health campaign, communications must also address rationales for vaccine hesitancy that vary among individuals and communities, and directly address the gist of their concerns in an empathetic, non-judgmental manner. We will conduct a randomized controlled trial to test the effectiveness of empathic, relationship-building interactions relative to standard provision of information on social media to address COVID-19 vaccine hesitancy.


Eligibility criteria: Inclusion Criteria:

* reside in the U.S.
* unvaccinated from COVID-19
* Use Facebook regularly (at least 1/day)

Exclusion Criteria:

* age \<18 years
* do not reside in the U.S.
* vaccinated from COVID-19
* do not use Facebook regularly (at least 1/day)

Primary outcomes:
measure: Engagement and satisfaction with the program
timeFrame: 4 weeks
Secondary outcomes:
measure: Proportion of participants getting the COVID-19 vaccine
timeFrame: 4 weeks
measure: Change in COVID-19 vaccination intention
timeFrame: 4 weeks
measure: Change in intention to encourage others to get the COVID-19 vaccine
timeFrame: 4 weeks
measure: Change in COVID-19 vaccine confidence
timeFrame: 4 weeks
measure: Change in general vaccine confidence
timeFrame: 4 weeks
measure: Change in vaccine hesitancy
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Washington
country: United States
facility: George Washington University
state: District of Columbia
Study officials:
References:
Clinical trial NCT03254498: Detection in Tandem Endocuff Cap Trial
Official title: Is Endocuff Vision Assisted Colonoscopy Superior to Cap Assisted Colonoscopy to Detect Adenomas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Colonic Neoplasms
Adenomas Serrated
Colo-rectal Cancer
Colon Adenoma
Keywords: colonic adenoma
serrated polyps
caecal intubation time
withdrawal time
polyp miss rate
Lead sponsor: London North West Healthcare NHS Trust
Sponsor class: OTHER
First posted: 2017-08-18
Enrollment: 154
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: It is a randomised back to back study to compare the performance of cap assisted colonoscopy (CAC) and Endocuff assisted colonoscopy (EAC)
Primary purpose: DIAGNOSTIC

Brief summary: A randomised back to back study comparing cap and Endocuff to detect adenomas during colonoscopy


Eligibility criteria: Inclusion Criteria:

1. Age 18 years and over
2. Referral for surveillance, or diagnostic colonoscopy
3. Ability to give informed consent

Exclusion Criteria:

1. Absolute contraindications to colonoscopy
2. Established or suspicion of large bowel obstruction or pseudo-obstruction
3. Known colon cancer or polyposis syndromes
4. Known colonic strictures
5. Known severe diverticular segment (that is likely to impede colonoscope passage)
6. Patients with active colitis (ulcerative colitis, Crohn's colitis, diverticulitis, infective colitis)
7. Patients lacking capacity to give informed consent
8. Pregnancy
9. Patients who are on clopidogrel, warfarin, or other new generation anticoagulants who have not stopped this for the procedure

Primary outcomes:
measure: Adenoma miss rate
timeFrame: 1 day
Secondary outcomes:
measure: Mean adenoma per procedure
timeFrame: 1 day
measure: Endocuff or cap exchange
timeFrame: 1 day
measure: Ceacal intubation and withdrawal time
timeFrame: 1 day
measure: miss rate of advanced polyps
timeFrame: 1 day
measure: Comfort score
timeFrame: 1 day
Other outcomes:
measure: comparison of surveillance intervals
timeFrame: Once histology is available usually takes 10-14 days
Locations:
city: Harrow
country: United Kingdom
facility: NorthWest London Hospitals - NOrthwick park hospital
state: Middlesex
Study officials:
affiliation: St Mark's Hospital, Northwest London Hospitals NHS Trust
name: Brian P Saunders, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rameshshanker R, Tsiamoulos Z, Wilson A, Rajendran A, Bassett P, Tekkis P, Saunders BP. Endoscopic cuff-assisted colonoscopy versus cap-assisted colonoscopy in adenoma detection: randomized tandem study-DEtection in Tandem Endocuff Cap Trial (DETECT). Gastrointest Endosc. 2020 Apr;91(4):894-904.e1. doi: 10.1016/j.gie.2019.11.046. Epub 2019 Dec 10.